For some very old, immunocompromised or very at-risk people, curative and preventive treatments are available alongside vaccination, which may not be effective enough for them.
Article written by
Posted
Update
Reading time : 1 min.
France is enriching its therapeutic arsenal against Covid-19. In addition to the planned delivery of an antiviral, Paxlovid, at the end of January, a new monoclonal antibody, Sotrovimab, must arrive on the territory from Friday January 21. In total, France has ordered 20,000 doses of this treatment developed by the Vir Biotechnology and GSK laboratories.
For some very old, immunocompromised or very at-risk people, curative and preventive treatments are indeed available alongside vaccination, which may not be effective enough for them. “Despite vaccination, people at risk must consult very quickly in the event of Covid”, therefore underlined the Ministry of Health, considering nevertheless that “vaccination remains our main weapon”.
Effective against Omicron, the Sotrovimab has the disadvantage of being administered by intravenous injection in the hospital or via hospitalization at home within five days of the onset of the first symptoms. The Paxlovid pill, from Pfizer, is administered orally at the rate of three tablets per day for five days.